Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 2/20 | 0.60 |
| ▸ | KIF11 | P52732 | 6/20 | 0.57 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.56 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.47 |
| ▸ | GCK | P35557 | 1/20 | 0.46 |
| ▸ | GCKR | Q14397 | 1/20 | 0.46 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.44 |
| ▸ | FEN1 | P39748 | 2/20 | 0.44 |
| ▸ | CLK1 | P49759 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL177728 | 0.83 | KMT2A (0.52) | NPBWR1KIF11PIK3CDGCKGCKR | |
| SCHEMBL29441491 | 0.83 | KMT2A (0.52) | NPBWR1KIF11PIK3CDGCKGCKR | |
| SCHEMBL30337416 | 0.82 | PIK3CD (0.70) | NPBWR1PIK3CDMKNK1MKNK2LTA4H | |
| SCHEMBL29818212 | 0.82 | KIF11 (0.59) | KIF11MKNK1MKNK2MAP4K4ALOX5AP | |
| Hydrochloric Acid SCHEMBL1865537 | 0.81 | KMT2A (0.50) | NPBWR1KIF11PIK3CDGCKGCKR | |
| Ammonia Solution, Strong SCHEMBL27669845 | 0.81 | KMT2A (0.50) | NPBWR1KIF11PIK3CDGCKGCKR | |
| Methane SCHEMBL3555245 | 0.81 | KMT2A (0.50) | NPBWR1KIF11PIK3CDGCKGCKR | |
| SCHEMBL30704262 | 0.80 | MAP4K4 (0.62) | NPBWR1KIF11PIK3CDMKNK2MAP4K4 | |
| SCHEMBL2762443 | 0.80 | PIK3CD (0.56) | NPBWR1PIK3CDMKNK1MKNK2MAP4K4 | |
| SCHEMBL28051302 | 0.80 | MAP4K4 (0.62) | NPBWR1KIF11PIK3CDMKNK2MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102812006-B | Novel antimalaria reagent | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2016-01-20 | — | — | CN | claimed |
| US-10858375-B2 | Nitrogenous cyclic compound and color changing film comprising same | LG CHEM, LTD. (KR) | 2020-12-08 | — | — | US | disclosed |
| US-10711015-B2 | Nitrogen-containing compound and color conversion film comprising same | LG CHEM, LTD. (KR) | 2020-07-14 | — | — | US | disclosed |
| US-20200032138-A1 | NITROGEN-CONTAINING COMPOUND AND COLOR CONVERSION FILM COMPRISING SAME | LG CHEM, LTD. (KR) | 2020-01-30 | — | — | US | disclosed |
| CN-102812006-B | Novel antimalaria reagent | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2016-01-20 | — | — | CN | disclosed |
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| US-8349844-B2 | Substituted pyrazolo [1,5-A] pyrimidines as metabotropic glutamate antagonists | HOFFMANN-LA ROCHE INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120041002-A1 | SUBSTITUTED PYRAZOLO [1,5-A] PYRIMIDINES AS METABOTROPIC GLUTAMATE ANTAGONISTS | GATTI MCARTHUR SILVIA (CH) | 2012-02-16 | — | — | US | disclosed |
| US-8093263-B2 | Substituted pyrazolo [1,5-a] pyrimidines as metabotropic glutamate antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8063048-B2 | Acetylenyl-pyrazolo-pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-7446113-B2 | Acetylenyl-pyrazolo-pyrimidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2008-11-04 | — | — | US | disclosed |
| EP-1934214-A1 | OXADIAZOLYL PYRAZOLO-PYRIMIDINES AS MGLUR2 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-25 | — | — | EP | disclosed |
| EP-1863818-A1 | ACETYLENYL-PYRAZOLO-PVRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-12-12 | — | — | EP | disclosed |
| US-20070167460-A1 | Acetylenyl-pyrazolo-pyrimidine derivatives | MCARTHUR SILVIA G | 2007-07-19 | — | — | US | disclosed |
| US-7238808-B2 | Acetylenyl-pyrazolo-pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-07-03 | — | — | US | disclosed |
| WO-2007039439-A1 | OXADIAZOLYL PYRAZOLO-PYRIMIDINES AS MGLUR2 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| US-20070072879-A1 | Novel compounds as metabotropic glutamate receptor antagonists | HOFFMANN-LA ROCHE INC. | 2007-03-29 | — | — | US | disclosed |
| US-20060217387-A1 | Acetylenyl-pyrazolo-pyrimidine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2006-09-28 | — | — | US | disclosed |
| WO-2006099972-A1 | ACETYLENYL-PYRAZOLO-PVRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-09-28 | — | — | WO | disclosed |
| WO-2005005382-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200032138-A1 | NITROGEN-CONTAINING COMPOUND AND COLOR CONVERSION FILM COMPRISING SAME | MYB, NUDC, BLVRB | NPBWR1 1363/4885KIF11 4489/4885PIK3CD 3498/4885 |
| US-20060217387-A1 | Acetylenyl-pyrazolo-pyrimidine derivatives | NAT1, TPMT, ACAT1 | NPBWR1 2345/4885KIF11 1003/4885PIK3CD 3641/4885 |
| US-20120041002-A1 | SUBSTITUTED PYRAZOLO [1,5-A] PYRIMIDINES AS METABOTROPIC GLUTAMATE ANTAGONISTS | GRM1, GRM2, GRM3 | NPBWR1 309/4885KIF11 1243/4885PIK3CD 2407/4885 |
| US-20070167460-A1 | Acetylenyl-pyrazolo-pyrimidine derivatives | NAT1, ADORA2B, TPMT | NPBWR1 2568/4885KIF11 1180/4885PIK3CD 3540/4885 |
| US-10711015-B2 | Nitrogen-containing compound and color conversion film comprising same | MYB, NUDC, BLVRB | NPBWR1 1363/4885KIF11 4489/4885PIK3CD 3498/4885 |
| US-10858375-B2 | Nitrogenous cyclic compound and color changing film comprising same | CRY1, MYB, NUDC | NPBWR1 1819/4885KIF11 4478/4885PIK3CD 2422/4885 |
| US-20070072879-A1 | Novel compounds as metabotropic glutamate receptor antagonists | GRM1, GRM2, GRM3 | NPBWR1 217/4885KIF11 1593/4885PIK3CD 2987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.